发明名称 Methods of inhibiting vascular endothelial growth factor activity
摘要 The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.
申请公布号 US9273113(B2) 申请公布日期 2016.03.01
申请号 US201213584241 申请日期 2012.08.13
申请人 GENENTECH, INC. 发明人 Davis-Smyth Terri Lynn;Chen Helen Hsifei;Presta Leonard;Ferrara Napoleone
分类号 A61K38/18;C07K14/71;C12N15/62;C07K16/28;A61K38/00 主分类号 A61K38/18
代理机构 代理人 Day Jones
主权项 1. A method of therapeutically treating a mammal for a condition associated with undesired vascularization, said method comprising administering to said mammal a therapeutically effective amount of a composition comprising (i) a chimeric VEGF receptor protein being capable of binding to VEGF and thereby exerting an inhibitory effect thereon, wherein said chimeric VEGF receptor protein comprises immunoglobulin-like domains 2 and 3 of the flt-1 and/or the KDR receptor, wherein said immunoglobulin-like domain 2 of the flt-1 and/or KDR receptor comprises an amino acid sequence of SEQ ID NO:49 or SEQ ID NO:50; and (ii) a pharmaceutically acceptable carrier.
地址 South San Francisco CA US